Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GELESIS HOLDINGS, INC.

(GLS)
  Report
Real-time Estimate Cboe BZX  -  02:52 2022-12-07 pm EST
0.3270 USD   -11.62%
11/22Gelesis reports upcoming participation in wolfe research's annual consumer growth conference
AQ
11/21Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference
BU
11/21Gelesis Holdings, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

Number of employees : 113 people.
Managers
Name Title Age Since
Yishai Zohar President, Chief Executive Officer & Director 58 2022
Elliot Maltz Treasurer, Chief Financial & Accounting Officer 37 2022
Harry L. Leider, Dr. Chief Medical Officer 63 2022
Elaine Chiquette, Dr. Chief Scientific Officer 55 2022
David Pass, Dr. Chief Operating & Commercial Officer 53 2022
Alessandro Sannino, Dr. Lead Project Scientist 49 2022
Members of the board
Name Title Age Since
Clayton Christopher Independent Director 48 2022
Dominic Anthony Charles Perks Independent Director 44 2022
Alison K. Bauerlein Independent Director 39 2022
Paul R. Fonteyne Independent Director 60 2022
Raju S. Kucherlapati, Dr. Independent Director 78 2022
Kathryn Cavanaugh Independent Director 47 2022
Jane Wildman Independent Director 60 2022
Yishai Zohar President, Chief Executive Officer & Director 58 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 73,033,504 34,728,241 47.6% 0 0.0% 47.6%
Shareholders
NameEquities%
Puretech Health LLC 16,727,582 22.9%
HPSO SPV Ltd. 12,181,993 16.7%
SSD2 LLC 12,056,626 16.5%
China Medical System Holdings Limited 4,501,770 6.17%
Pacific Investment Management Co. LLC 3,165,411 4.34%
The Vanguard Group, Inc. 2,915,964 4.00%
Vitruvian Partners LLP 1,876,106 2.57%
Yishai Zohar 1,426,014 1.95%
Aristeia Capital LLC 1,412,642 1.94%
Periscope Capital, Inc. 1,400,000 1.92%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gelesis Holdings, Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
GELESIS HOLDINGS, INC.-96.29%27
JOHNSON & JOHNSON4.51%460 411
ELI LILLY AND COMPANY33.69%350 179
ABBVIE INC.20.92%289 437
NOVO NORDISK A/S21.77%285 921
PFIZER, INC.-14.09%279 038
MERCK & CO., INC.42.13%276 181
ROCHE HOLDING AG-19.49%268 288
ASTRAZENECA PLC28.49%211 451
NOVARTIS AG6.23%195 283
BRISTOL-MYERS SQUIBB COMPANY29.43%177 394
AMGEN INC.26.64%151 158
SANOFI-3.60%112 649
GILEAD SCIENCES, INC.21.14%110 323
GSK PLC-15.56%68 976
DAIICHI SANKYO CO., LTD.48.38%60 949
BAYER AG12.53%54 661
TAKEDA PHARMACEUTICAL COMPANY LIMITED26.87%45 326
CHUGAI PHARMACEUTICAL CO., LTD-2.36%43 949
JIANGSU HENGRUI MEDICINE CO., LTD.-19.98%36 373
ASTELLAS PHARMA INC.11.84%27 932